Enhanced Light Utilization in Semitransparent Organic Photovoltaics Using an Optical Outcoupling Architecture

Buildingâ integrated photovoltaics employing transparent photovoltaic cells on window panes provide an opportunity to convert solar energy to electricity rather than generating waste heat. Semitransparent organic photovoltaic cells (STâ OPVs) that utilize a nonfullerene acceptorâ based nearâ infrared (NIR) absorbing ternary cell combined with a thin, semitransparent, high conductivity Cuâ Ag alloy electrode are demonstrated. A combination of optical outcoupling and antireflection coatings leads to enhanced visible transmission, while reflecting the NIR back into the cell where it is absorbed. This combination of coatings results in doubling of the light utilization efficiency (LUE), which is equal to the product of the power conversion efficiency (PCE) and the average photopic transparency, compared with a conventional semitransparent cell lacking these coatings. A maximum LUE = 3.56 ± 0.11% is achieved for an STâ OPV with a PCE = 8.0 ± 0.2% at 1 sun, reference AM1.5G spectrum. Moreover, neutral colored STâ OPVs are also demonstrated, with LUE = 2.56 ± 0.2%, along with Commission Internationale d’Eclairage chromaticity coordinates of CIE = (0.337, 0.349) and a color rendering index of CRI = 87.An efficient and neutral colored semitransparent organic photovoltaic cell (STâ OPV) is realized by utilizing a nearâ infrared (NIR) absorbing ternary cell combined with a thin, semitransparent, highâ conductivity Cuâ Ag alloy electrode. A combination of optical outcoupling and antireflection coatings leads to enhanced visible transmission, while reflecting the NIR back into the cell where it is absorbed.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151812/1/adma201903173.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/151812/2/adma201903173_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/151812/3/adma201903173-sup-0001-S1.pd

SU(3) realization of the rigid asymmetric rotor within the IBM

It is shown that the spectrum of the asymmetric rotor can be realized quantum mechanically in terms of a system of interacting bosons. This is achieved in the SU(3) limit of the interacting boson model by considering higher-order interactions between the bosons. The spectrum corresponds to that of a rigid asymmetric rotor in the limit of infinite boson number.Comment: 9 pages, 2 figures, LaTeX, epsfi

Antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged from 50 to 102 years

ObjectivesTo assess antibody responses to an inactivated SARS-CoV-2 vaccine in individuals aged 50 and older.MethodsWe conducted a post-market cross-sectional seroepidemiology study. We recruited 4,632 vaccinated individuals aged 50 and older, measured their total serum SARS-CoV-2-specific antibody (TA), and collected correlates. The primary outcome was the geometric mean titer (GMT) of TA, and the secondary outcome was the decline of TA with age. Univariate, bivariate, and multivariate analyses were used to examine the associations of the TA GMT with age, and trend analyses were used to test whether their associations were significant.ResultsAll participants had a detectable TA, which was generally at a low level across all age groups. The TA GMT (95% CI) in AU/mL was 3.05 (2.93, 3.18); the corresponding arithmetic mean (95% CI) was 17.77 (16.13, 19.42) in all participants and 4.33 (3.88, 4.84), 3.86 (3.49, 4.28), 3.24 (2.92, 3.59), 2.77 (2.60, 2.96), and 2.65 (2.48, 2.83) in the age groups of 50-54, 55-59, 60-64, 65-74, and 75 years or older, respectively. The TA GMT decreased with age with a Ptrend < 0.001. The TA GMT was significantly lower in those with hypertension or diabetes compared to those with neither.ConclusionThe inactivated SARS-CoV-2 vaccine is effective in individuals aged 50 and older. This is the first study that has found an inverse dose-response relationship between ages and the low-level TAs. Older people, especially those with chronic diseases, should get the SARS-CoV-2 vaccine, and their vaccination frequency, dose, and method may need to be different from those of younger people

Overexpression of YAP 1 contributes to progressive features and poor prognosis of human urothelial carcinoma of the bladder

BACKGROUND: Yes-associated protein 1 (YAP 1), the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene in multiple tumors. However, the expression dynamics of YAP 1 in urothelial carcinoma of the bladder (UCB) and its clinical/prognostic significance are unclear. METHODS: In this study, the methods of quantitative real-time polymerase chain reaction (qRT-PCR), Western blotting and immunohistochemistry (IHC) were utilized to investigate mRNA/ protein expression of YAP 1 in UCBs. Spearman’s rank correlation, Kaplan-Meier plots and Cox proportional hazards regression model were used to analyze the data. RESULTS: Up-regulated expression of YAP 1 mRNA and protein was observed in the majority of UCBs by qRT-PCR and Western blotting, when compared with their paired normal bladder tissues. By IHC, positive expression of YAP 1 was examined in 113/213 (53.1%) of UCBs and in 6/86 (7.0%) of normal bladder specimens tissues. Positive expression of YAP 1 was correlated with poorer differentiation, higher T classification and higher N classification (P < 0.05). In univariate survival analysis, a significant association between positive expression of YAP 1 and shortened patients’ survival was found (P < 0.001). In different subsets of UCB patients, YAP 1 expression was also a prognostic indicator in patients with grade 2 (P = 0.005) or grade 3 (P = 0.046) UCB, and in patients in pT1 (P = 0.013), pT2-4 (P = 0.002), pN- (P < 0.001) or pT2-4/pN- (P = 0.004) stage. Importantly, YAP 1 expression (P = 0.003) together with pT and pN status (P< 0.05) provided significant independent prognostic parameters in multivariate analysis. CONCLUSIONS: Our findings provide evidences that positive expression of YAP 1 in UCB may be important in the acquisition of an aggressive phenotype, and it is an independent biomarker for poor prognosis of patients with UCB